celiac disease

[Science] CD8+ T expressing inhibitory killer cell immunoglobulin-like receptors cells efficiently eliminated pathogenic gliadin-specific CD4+ T cells from celiac disease patients’ leukocytes in vitro.

[Peptides] The authors demonstrate the roles and mechanisms of gastrointestinal polypeptides, especially somatostatin and vasoactive intestinal peptide, in intestinal barrier regulation.

[Provention Bio, Inc.] Provention Bio, Inc. announced positive interim results from PROVENT, a first-in-human study of PRV-101, a polyvalent inactivated coxsackievirus B vaccine candidate targeting all five key CVB strains associated with type 1 diabetes autoimmunity.

[PLOS ONE] In this first single-cell RNA-seq study of tetramer-sorted T cells from untreated celiac disease patients blood, investigators found that gluten-specific T cells showed distinct transcriptomic profiles consistent with activated effector memory T cells that shared features with Th1 and follicular helper T cells.

[Beyond Celiac] Beyond Celiac announced the granting of a two-year established investigator grant award to the University of Sheffield, United Kingdom. The $209,000 investment from Beyond Celiac will make it possible for scientists to expand investigation of the neurological and neuropsychological manifestations of celiac disease and gluten-related disorders.

[Synthetic Biologics, Inc.] Synthetic Biologics, Inc., a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal diseases, announced that patient dosing and observation has been completed in its Phase I clinical trial of SYN-020 intestinal alkaline phosphatase.